Top

Breast Cancer Research and Treatment

Published in:

01-11-2011 | Letter to the Editor

Anti-cytokeratin CAM 5.2 (B.D. Biosciences) has a primary reactivity with CK 7 and CK 8 (48 and 52 kD) rather than with the smaller molecular weight keratin breakdown fractions (50, 43, and 38 kD)

Authors: Chung-Chin Yao, Wea-Lung Lin, Ming-Yung Lee, Chih-Ping Han

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Excerpt

To the Editor …

Available only for authorised users

Amemiya Y, Yang W, Benatar T, Nofech-Mozes S, Yee A, Kahn H, Holloway C, Seth A (2011) Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Breast Cancer Res Treat 126(2):373–384PubMedCrossRef

Makin CA, Bobrow LG, Bodmer WF (1984) Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol 37:975–983PubMedCrossRef

BD Biosciences. Anti-cytokeratin (CAM 5.2) reagent for in vitro diagnostic use. 50 tests per vial–catalog no. 349205. Data sheet, http://www.bdbiosciences.com/external_files/is/doc/tds/Datasheets_RUO/live/web_enabled/23-1336-09-347653-347204-349205-DS-ruo.pdf. Accessed 11 May 2011

BD Biosciences. Anti-cytokeratin (CAM 5.2) reagent, http://www.bdbiosciences.com/ptProduct.jsp?prodId=62358&key=cam5.2&param=search&mterms=true. Accessed 11 May 2011

Smedts F, Ramaekers F, Robben H, Pruszczynski M, van Muijen G, Lane B, Leigh I, Vooijs P (1990) Changing patterns of keratin expression during progression of cervical intraepithelial neoplasia. Am J Pathol 136:657–668PubMed

Title: Anti-cytokeratin CAM 5.2 (B.D. Biosciences) has a primary reactivity with CK 7 and CK 8 (48 and 52 kD) rather than with the smaller molecular weight keratin breakdown fractions (50, 43, and 38 kD)
Authors: Chung-Chin Yao
Wea-Lung Lin
Ming-Yung Lee
Chih-Ping Han
Publication date: 01-11-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1633-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2011

CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status

Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care

Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity

COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy

Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society

Keynote webinar | Spotlight on antibody–drug conjugates in cancer